and, in patients with a single brain metastasis, improve overall survival. Bristol Haematology and Oncology Centre (BHOC) have been using stereotactic radiotherapy (SRS) to treat patients with brain metastasis since 2003. These are the results of our experience in patients with non-small cell lung cancer. Method: An electronic database identified patients treated by SRS with brain metastases from NSCLC. All patients treated at the BHOC were included (08/12/2003 to 01/09/2013). Data was collected retrospectively on the use of WBRT, control of the brain metastasis and survival from treatment. Results: Details were collected on 26 patients ranging in age between 50 and 70 years (median 62). 50% were male and 25 had a single metastasis treated. Where documented, performance status was 0 1. Median survival was 377.5 days, with a range of 40 days to more than 785 days. 23% of patients survive at this time; 88% survived more than 6 months; 54% have survived beyond 1 year. 23% of patients had documentation of CNS progression. 46% received WBRT: 33% prior to SRS and 66% subsequent to SRS. Conclusion: This small series suggests NSCLC patients, with a single brain metastasis and good performance score, treated with SRS can achieve good local control with over half of patients living beyond a year.